Clinical trials: Patient With Schizophrenia Spectrum Disorder
DSM-5 Schizophrenia
Impact of Caregiver Beliefs on Adherence to Antipsychotic Medications in Patients With Schizophrenia
Only one third of patients with schizophrenia are observant to their treatment knowing that the lack of adherence to treatment is one of the most important predictors of relapse.
- Trial name
- CroyAid-SCZ (NCT03471013)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Schizophrenia Spectrum Disorders (SSD)
Psychotherapy for Self-Disorders in Schizophrenia Spectrum Disorder
The primary goal of the VITALIZE study is to evaluate the feasibility of SELF-7, a novel phenomenologically informed psychotherapy for self-disorders, as an add-on to standard psychiatric outpatient treatment - Flexible Assertive…
- Trial name
- VITALIZE (NCT07841418)
- Testing
- SELF-7, F-ACT
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Schizophrenia
Improving Insight in Patients Diagnosed With Schizophrenia
Background: Rehospitalisation and discontinued treatment are common among patients with schizophrenia and is often associated with lack of insight into the illness.
- Trial name
- GEBRCT (NCT01282307)
- Testing
- Guided Self-Determination GSD
- Where
- Denmark
- Volunteers
- 101 people
- Sponsor
- University of Aarhus
Schizophrenia
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
This study is a ten-week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 20 obese stable olanzapine-treated patients with schizophrenia or schizoaffective…
- Trial name
- NCT00351936
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
An Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With Schizophrenia
The objective of the present study was to investigate the possibility of using L-lysine, an amino acid that occurs naturally in food and which interferes with nitric oxide (NO) production, for the treatment of schizophrenia.
- Trial name
- NCT00996242
- Testing
- L-lysine
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Göteborg University
Schizophrenia
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of…
- Trial name
- NCT01192880
- Testing
- Bitopertin, Antipsychotics
- Where
- 103 sites in United States, Bulgaria and 5 more
- Volunteers
- 625 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia Spectrum and Other Psychotic Disorders
Cognitive Behavior Therapy for Patients With Psychoses.
Patients with psychoses are randomized either to group treatment (ACT) or individual CBT for 18 sessions.
- Trial name
- NCT03501888
- Testing
- Cognitive Behavior Therapy, Acceptance and Commitment Therapy
- Volunteers
- 16 people
- Sponsor
- Karolinska Institutet
Schizophrenia
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
The purpose of this study is to assess the effectiveness, safety and tolerability of flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully treated by oral antipsychotics and with acute…
- Trial name
- NCT01685931
- Testing
- Paliperidone Palmitate
- Where
- 17 sites in China
- Volunteers
- 617 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia, Psychotic Disorders
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.
- Conditions
- Schizophrenia, Psychotic Disorders, Substance Abuse, Alcohol Abuse
- Trial name
- NCT00130923
- Testing
- Risperidone Long Acting, oral risperidone
- Where
- 8 sites in United States
- Volunteers
- 95 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Pediatric
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT04779177
- Testing
- Lumateperone 42 mg, Lumateperone 28 mg
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
This study design is subject to relevant SFDA regulations about clinical trials. Patients will be screened for inclusion into the study at the initial visit(240 patients to be recruited) and then undergo a minimum of 3-7 day's…
- Trial name
- NCT00202007
- Testing
- Aripiprazole tablet, 5-30mg/day, oral, 6 weeks, Risperidone tablet, 1-6mg/day, oral, 6 weeks
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
Real-World Impact of TV-44749 in Adults With Schizophrenia
The main purpose of this trial is to evaluate how TV-44749 (olanzapine long-acting injectable) works in routine clinical practice for adults with schizophrenia.
- Trial name
- RADIANCE (NCT07913100)
- Testing
- TV-44749
- Volunteers
- 1,085 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia Disorder
Assessment of Physical Activity, Balance, Muscle Strength, and Cognitive Function in Patients Diagnosed With Schizophrenia
Schizophrenia is a serious mental health condition that affects individuals' thinking, perception, emotional responses, and behavior.
- Trial name
- NCT07141966
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Schizophrenia
The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia
The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia.
- Trial name
- NCT00523445
- Testing
- Varenicline(Chantix)
- Where
- 5 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Inje University
Tardive Dyskinesia, Schizophrenia
Extract of Ginkgo Biloba and Tardive Dyskinesia
The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia
- Trial name
- EGBTD (NCT00672373)
- Testing
- Extract of Ginkgo Biloba (EGb-761 capsules)
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Beijing HuiLongGuan Hospital
Schizophrenia
The Effects of Different Modalities of Exercise in Patients With Schizophrenia
Introduction: Numerous studies support the practice of different physical exercise modalities as an effective treatment to address the different problems associated with schizophrenia, reporting that they result in significant…
- Trial name
- NCT04987151
- Testing
- Experimental-Strength training, Experimental-Aerobic training, Experimental-Strength/Aerobic training
- Where
- Spain
- Volunteers
- 105 people
- Sponsor
- Cardenal Herrera University
Medication Adherence
A Smartphone App on Medication Adherence
This is an experimental study which aims to explore the effectiveness of a smartphone app for medication adherence (MedAdhere app) among schizophrenic patients for eight weeks.
- Trial name
- App (NCT05892120)
- Testing
- the MedAdhere app
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Schizophrenia
Prucalopride for Cognitive Functioning in Schizophrenia
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition.
- Trial name
- NCT06474286
- Testing
- Prucalopride 1 MG
- Where
- India
- Volunteers
- 34 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
The purpose of this study is to determine whether pregnenolone will demonstrate significant improvements in cognitive functioning and negative symptoms compared to patients receiving placebo.
- Trial name
- NCT00894842
- Testing
- Pregnenolone
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- National Research Foundation, Singapore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.